Associate editor: P.C. MolenaarCOX-dependent mechanisms involved in the antinociceptive action of NSAIDs at central and peripheral sites
Introduction
Non-steroidal anti-inflammatory drugs (NSAIDs) are among the most widely prescribed and widely used drugs in the management of pain, especially pain associated with inflammatory conditions. Despite the wide use of NSAIDs during the last century (the first NSAID, aspirin, was developed in the late 1800s), for a long period only little was known about the mode of action of these drugs. It was not until the 1970s that investigations into the mode of action of aspirin-like drugs were taken over by prostaglandin researchers, who showed an association between prostaglandin production and the action of aspirin-like drugs (Vane, 1964). In 1971, Vane discovered that NSAIDs could inhibit prostaglandin synthesis and proposed that this mechanism was the basis of their pharmacological action (Vane, 1971). This hypothesis was supported by other experimental data demonstrating the presence of prostaglandins at sites of inflammation (Willis, 1969, Di Rosa et al., 1971) and their ability to reproduce some of the cardinal signs of inflammation (Arora et al., 1970). The biomolecular target of NSAIDs was not identified until 1976 when a purified and enzymatically active cyclooxygenase (COX) was isolated from sheep vesicular glands (Hemler & Lands, 1976). It took several years more i.e. until the late 1980s before it was discovered that COX exists in at least two isoforms (Kujubu et al., 1991, Hla & Neilson, 1992), COX-1 and COX-2, and that “classical” NSAIDs are non-selective inhibitors of both isozymes (Xie et al., 1992).
Initially, the principle mode of the antinociceptive action of NSAIDs was considered to be related to their anti-inflammatory action and was thought to be due solely to the inhibition of prostaglandin production at the site of inflammation. This argument has its origin in the experimental observations of Horton (1963), Willis (1969), Juhlin and Michaelsson (1969), Crunkhorn and Willis (1971), Karim (1971) and, particularly, those of Ferreira (1972). By estimating pain in healthy volunteers following the intradermal administration of various inflammatory mediators (histamine, bradykinin and alprosadil (PGE1)), Ferreira could show that whilst PGE2 ‘per se’ produced no pain, its presence was essential for the induction of pain by histamine and bradykinin. These findings form the basis of the currently accepted view that PGs are not generally algogenic but act as sensitizing agents for enhancing the nociceptive properties of various inflammatory mediators. Additional evidence for the concept that NSAIDs exert their anti-nociceptive action peripherally comes from tissue distribution data obtained from whole-body autoradiography after administration of various NSAIDs in rats (Brune, 1974). In particular, it was shown that NSAIDs, because of the acidic moiety, can be extensively accumulated in inflamed tissues, where they exert their pharmacological action. At that time, the distribution of NSAIDs in other tissues, in particular in the CNS, was construed only as an explanation for the organ specific toxicity and was not thought to be related to their antinociceptive action (Brune, 1974).
The traditional belief that NSAIDs have exclusively a peripheral mode of action was not challenged until the beginning of the 1990s in the wake of the growing evidence that the anti-inflammatory and the antinociceptive effects of NSAIDs are unrelated (McCormack & Brune, 1991). So, an existence of some central antinociceptive mechanisms, an idea initially put forward by Hazlick as early as 1926 (Jurna, 1997), has been suggested (Ferreira et al., 1978, Carlsson et al., 1988). Although various mechanisms have been proposed to account for central effects of NSAIDs (Bjorkman, 1995), inhibition of prostaglandin synthesis (Abdel-Halim et al., 1978, Ferreira et al., 1978) in the CNS, and particularly in the spinal cord (Jurna et al., 1992, Malmberg & Yaksh, 1992), appears to be a property of all NSAIDs. Furthermore, the finding that both COX isozymes, i.e. COX-1 and COX-2, are expressed in the CNS (Kaufmann et al., 1997) and the observation that experimental induction of peripheral inflammation is associated with an increase in the expression of COX-2 in the spinal cord (Beiche et al., 1996) have been used as evidence supporting a central antinociceptive mechanism of action of NSAIDs (Vasquez et al., 2001, Vanegas, 2002).
This review of the central and peripheral antinociceptive mechanisms of action of NSAIDs mainly focuses on the inhibition of cyclooxygenase-mediated prostaglandin synthesis, as a class-like pharmacological property of NSAIDs. Cyclooxygenase-independent actions of NSAIDs, including cellular mechanisms mediated via interference with transcription factors (Tegeder et al., 2001b) and direct modulation of the activities of various ion channels (Lee et al., 2003), have so far only been observed with a few NSAIDs and are therefore not discussed here in detail.
The mechanisms and clinical manifestations involved in inflammatory pain, a condition commonly treated with NSAIDs, are dealt with first and this is followed by a discussion on the location and regulation of the main target of NSAIDs, cyclooxygenases at the central and peripheral sites. Biochemical aspects of prostaglandin synthesis are presented and special attention is given to the mechanisms of the prostaglandin-mediated hyperalgesia. The final section deals with the antihyperalgesic action of NSAIDs where attention is given to the currently available experimental and clinical evidence supporting their peripheral and central mechanisms. The contribution of both mechanisms to the overall antinociceptive action of this class of analgesics is discussed.
Section snippets
Inflammatory pain
The nociceptive signalling in physiological pain is initiated by activation of the specialized pain receptors (nociceptors), which are polymodal sensory fibres of the primary sensory neurons located in trigeminal and dorsal root ganglia (DRG). Although the nociceptors are able to respond to a wide range of stimulus modalities, different noxious stimuli generally cause activation of a single receptor [e.g. heat activates TRPV1-receptors (Caterina et al., 1999) and mechanical force, P2X3
Prostaglandin synthesis
Despite the diverse chemical structure of aspirin-like drugs, the antinociceptive effect of NSAIDs is mainly due to their common property of inhibiting cyclooxygenases involved in the formation of prostanoids. Prostanoids are formed by most cells and act as autocrine and paracrine lipid mediators. They are not stored but are synthesized de novo from membrane-released arachidonic acid mobilized by phospholipases (PLA2) when cells are activated by mechanical trauma, cytokines and growth factors,
Central and peripheral antihyperalgesic effects of non-steriodal anti-inflammatory drugs (NSAIDs)
NSAIDs are a disparate group of weakly acidic, highly protein-bound compounds having the common pharmacological property of inhibiting prostaglandin biosynthesis (Smith et al., 1994, Kirtikara et al., 2001). This inhibition results from a variety of effects on cyclooxygenases including the irreversible inactivation of COX (e.g. by aspirin) and reversible competitive inhibition of COX (e.g. with ibuprofen). NSAIDs usually normalise the increased pain threshold associated with inflammation rather
Conclusion
NSAIDs are potent antinociceptive agents, whose efficacy in reducing pain is widely recognized in various pain conditions, including post-surgical pain and chronic pain associated with arthritis and cancer. Although NSAIDs have long been used in clinical practice, opinion on the mechanism of their antihyperalgesic action remains controversial. According to published findings, it appears that the inhibition of prostaglandin synthesis by NSAIDs takes place at the site of peripheral inflammation
Acknowledgment
The work of the authors is supported by the Deutsche Forschungsgemeinschaft (DFG 695/2-1) and the BMBF 01EM0103.
The authors are grateful to Dr. B.G. Woodcock for the valuable editorial assistance with the manuscript.
References (166)
- et al.
Inhibition of prostaglandin synthesis in rat brain
Acta Pharm Toxicol (Copenh)
(1978) - et al.
PGE2 selectively blocks inhibitory glycinergic neurotransmission onto rat superficial dorsal horn neurons
Nature
(2002) - et al.
A tetrodotoxin-resistant voltage-gated sodium channel expressed by sensory neurons
Nature
(1996) - et al.
Distribution of cyclooxygenase isoforms in murine chronic granulomatous inflammation: implications for future anti-inflammatory therapy
J Pathol
(1995) - et al.
The role of prostaglandin E1 in inflammatory process in the rat
Int Arch Allergy Appl Immunol
(1970) - et al.
Direct activation of rat spinal dorsal horn neurons by prostaglandin E2
J Neurosci
(2001) - et al.
Involvement of Na+-channels in pain pathways
Trends Pharmacol Sci
(2001) - et al.
Nociception in cyclooxygenase isozyme-deficient mice
Proc Natl Acad Sci U S A
(2000) - et al.
Clinical pharmacokinetics of nonsteroidal anti-inflammatory drugs in the cerebrospinal fluid
Biomed Pharmacother
(1989) - et al.
Plasma and cerebrospinal fluid concentrations of indomethacin in humans: relationship to analgesic activity
Eur J Clin Pharmacol
(1990)
Stereoselective disposition of ibuprofen enantiomers in human cerebrospinal fluid
Br J Clin Pharmacol
Piroxicam concentrations in plasma and synovial fluid after a single dose of piroxicam-beta-cyclodextrin
Int J Clin Pharmacol Ther
Expression of cyclooxygenase isoforms in the rat spinal cord and their regulation during adjuvant-induced arthritis
Inflamm Res
Localization of cyclooxygenase-2 and prostaglandin E2 receptor EP3 in the rat lumbar spinal cord
J Neuroimmunol
Up-regulation of cyclooxygenase-2 mRNA in the rat spinal cord following peripheral inflammation
FEBS Lett
Effects of antihyperalgesic drugs on experimentally induced hyperalgesia in man
Pain
Central antinociceptive effects of non-steroidal anti-inflammatory drugs and paracetamol: experimental studies in the rat
Acta Anaesthesiol Scand Suppl
Biodistribution of salicylates: a clue to the understanding of some effects and side effects
Agents Actions Suppl
Aspirin-like drugs may block pain independently of prostaglandin synthesis inhibition
Experientia
Peripheral and central antihyperalgesic effects of diclofenac in a model of human inflammatory pain
Clin Pharmacol Ther
Depression by morphine and the non-opioid analgesic agents, metamizol (dipyrone), lysine acetylsalicylate, and paracetamol, of activity in rat thalamus neurones evoked by electrical stimulation of nociceptive afferents
Pain
A capsaicin-receptor homologue with a high threshold for noxious heat
Nature
COX-3, a cyclooxygenase-1 variant inhibited by acetaminophen and other analgesic/antipyretic drugs: cloning, structure, and expression
Proc Natl Acad Sci U S A
Cutaneous reactions to intradermal prostaglandins
Br J Pharmacol
Cyclic AMP mediates the prostaglandin E2-induced potentiation of bradykinin excitation in rat sensory neurons
Neuroscience
A spinal mechanism for the peripheral anti-inflammatory action of indomethacin
Brain Res
The role of arachidonic acid oxygenation products in pain and inflammation
Annu Rev Immunol
The distribution of certain non-narcotic analgetic agents in the CNS of several species
J Pharmacol Exp Ther
Pharmacokinetics of non-steroidal anti-inflammatory drugs
Bailliere's Clin Rheumatol
Pharmacokinetics of nonsteriodal anti-inflammatory drugs in synovial fluid
Clin Pharmacokinet
Response properties of dorsal horn neurons: pharmacology of the dorsal horn
COX-3: in the wrong frame in mind
Immunol Lett
Effect of spinal cyclooxygenase inhibitors in rat using the formalin test and in vitro prostaglandin E2 release
Eur J Pharmacol
Effect of COX-1 and COX-2 inhibition on induction and maintenance of carrageenan-evoked thermal hyperalgesia in rats
J Pharmacol Exp Ther
Studies on the mediators of the acute inflammatory response induced in rats in different sites by carrageenan and turpentine
J Pathol
The intraspinal release of prostaglandin E2 in a model of acute arthritis is accompanied by an up-regulation of cyclo-oxygenase-2 in the spinal cord
Neuroscience
PGE2 modulates the tetrodotoxin-resistant sodium current in neonatal rat dorsal root ganglion neurones via the cyclic AMP-protein kinase A cascade
J Physiol
The cAMP transduction cascade mediates the PGE2-induced inhibition of potassium current in rat sensory neurons
J Physiol
Piroxicam-induced analgesia: evidence for a central component which is not opioid mediated
Experientia
Analgesic–antiinflammatory drugs inhibit orbicularis oculi reflexes in humans via a central model of action
Prog Neuro-Psychopharmacol Biol Psychiatry
Prostaglandins, aspirin-like drugs and analgesia
Nat New Biol
Prostaglandin hyperalgesia: IV. A metabolic process
Prostaglandins
Central and peripheral antialgesic action of aspirin-like drugs
Eur J Pharmacol
Measurement of the analgesic effects of aspirin with a new experimental algesimetric procedure
Pain
Differential effects of dipyrone, ibuprofen, and paracetamol on experimentally induced pain in man
Agents Actions
The cyclooxygenase isoforms: structural insights into the conversion of arachidonic acid to prostaglandins
Biochim Biophys Acta
The structures of prostaglandin endoperoxide H synthases-1 and -2
Prostaglandins Other Lipid Mediat
Antinociceptive actions of R(−)-flurbiprofen—a non-cyclooxygenase inhibiting 2-arylpropionic acid—in rats
Life Sci
Inducible cyclooxygenase may have anti-inflammatory properties
Nat Med
Hyperalgesic agents increase a tetrodotoxin-resistant Na+ current in nociceptors
Proc Natl Acad Sci U S A
Cited by (217)
The evaluation of the efficacy of etofenamate spray in postoperative cesarean pain: Randomized, double-blind, placebo-controlled trial
2023, Taiwanese Journal of Obstetrics and GynecologyPhospholipase signaling in inflammation and promiscuity of phospholipase active site ligands
2023, Phospholipases in Physiology and Pathology: Volumes 1-7